Formative oligodendrocyte progenitors for myelin replacement therapy

Leukodystrophies are a group of disorders that affect the white matter of the brain, which is crucial for normal brain function. These disorders mainly disrupt the glial cells, which support neurons. Neurons need a substance called myelin, produced by oligodendrocytes, to work properly. Myelin formation happens after birth and is essential for the brain’s full development.

Leukodystrophies are often caused by genetic mutations, many of which are not yet fully understood. Current research is exploring various treatments, including drugs, genetic repairs, and cell replacement therapies.

Our research focuses on a new stem cell therapy. This therapy aims to introduce healthy cells into the brain to produce functional myelin and support normal brain development. We identified a way to overcome limitations of previous cell therapy attempts. We identified how to control the cell type specificity of the transplanted cells to increase the generation of healthy oligodendrocytes. Our new method allows the production of millions of gene corrected cells of a patient ready for transplantation in a couple of weeks.

We plan to test if this new approach can more effectively replace faulty cells, improve brain development, and offer long-term benefits without needing prolonged immune suppression. Our technology will allow the safe use of the patient’s own cells and speeding up the time from diagnosis to treatment.